Measures to combat rare diseases and promote orphan drug development in Japan: government-funded special biomedical research programs to enhance basic and applied research

Expert Opinion on Orphan Drugs

Volumn 4, Issue 6, 2016, Pages 613-619

  Tang, Qi ^a,b   Song, Peipei ^c   Chen, Yu ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

intractable diseases; orphan drugs; Rare diseases; research project

Indexed keywords

NEW DRUG; ORPHAN DRUG;

APPLIED RESEARCH; BASIC RESEARCH; CLINICAL TRIAL (TOPIC); FUNDING; GOVERNMENT; HUMAN; JAPAN; LAW; MEDICAL RESEARCH; PRIORITY JOURNAL; RARE DISEASE; REVIEW;

EID: 84965000047     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1080/21678707.2016.1180244     Document Type: Review

References (34)

1. P.Song, J.Gao, Y.Inagaki, et al. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012 Feb;1(1):3–9.•• Review article includes discussion on orphan drugs research and development issues in Japan.
2. A.Schieppati, J.I.Henter, E.Daina, et al. Why rare diseases are an important medical and social issue. Lancet. 2008 Jun 14;371(9629):2039–2041.
3. W.Tang Hopes for intractable and rare diseases research. Intractable Rare Dis Res. 2013 Feb;2(1):1–2.
4. Rare Diseases Europe. About rare disease. 2009 [cited 2015 Dec10]. Available from: http://www.eurordis.org/about-rare-diseases.
5. L.Mei, P.Song, N.Kokudo, et al. Current situation and prospects of newborn screening and treatment for Phenylketonuria in China – compared with the current situation in the United States, UK and Japan. Intractable Rare Dis Res. 2013 Nov;2(4):106–114.
6. L.Mei, P.Song, L.Xu. Newborn screening and related policy against Phenylketonuria in China. Intractable Rare Dis Res. 2013 Aug;2(3):72–76.
7. P.Song. The ice bucket challenge: the public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseases. Intractable Rare Dis Res. 2014 Aug;3(3):94–96.
8. P.Song, J.Gao, Y.Inagaki, et al. Intractable and rare diseases research in Asia. Biosci Trends. 2012 Apr;6(2):48–51.
9. P.Song, N.Kokudo. Revision of measures to combat intractable diseases in Japan: three pillars will play an even greater role in the future. Intractable Rare Dis Res. 2013 Feb;2(1):33–34.• Article describing the revision of measures to combat rare diseases in Japan.
10. P.Song, J.Gao, N.Kokudo, et al. New opportunity for orphan drug development in Japan: early exploratory clinical trial bases promote drug translation from basic studies to clinical application. Intractable Rare Dis Res. 2012 May;1(2):95–97.•• Article describing the early exploratory clinical trial bases to promote drug translation from basic studies to clinical application in Japan.
11. Y.Inagaki, P.Song. Necessity of cooperation with government on publication of scientific research results for intractable diseases. Intractable Rare Dis Res. 2013 May;2(2):69–71.• Article emphasizes the importance of government-funded special biomedical research programs to combat rare diseases and orphan drugs.
12. W.Tang, M.Makuuchi. Intractable & rare diseases research. Intractable Rare Dis Res. 2012 Feb;1(1):1–2.•• Article emphasizes the importance of research programs to combat rare diseases and orphan drugs.
13. The Ministry of Health and Welfare. The outline of strategy against intractable diseases [Internet]. 1972 [cited 2015 Dec 20]. Available from: http://www.nanbyou.or.jp/pdf/nan_youkou.pdf
14. Japan Intractable Diseases Information Center. Strategies against intractable disease since 2015 [Internet]. 2015 [cited 2016 Jan 3]. Available from: http://www.nanbyou.or.jp/entry/4141.
15. Japan Intractable Diseases Information Center. Number of patient enrolled specified disease treatment research program [Internet]. 2015 [cited 2016 Jan 5]. Available from: http://www.nanbyou.or.jp/entry/1356.
16. The Japanese Ministry of Health, Labor, and Welfare. Revision of measures to combat intractable diseases [Internet]. 2013 [cited 2016 Jan 5]. Available from: http://www.mhlw.go.jp/stf/houdou/2r9852000002udoe.html
17. The Ministry of Health, Labour and Welfare. The results of early exploratory clinical trial bases for specific research areas [Internet]. 2011 [cited 2016 Jan 6]. Available from: http://www.mhlw.go.jp/stf/houdou/2r9852000001jym4.html.
18. Japan Intractable Diseases Information Center. The program of applied research to combat rare diseases [Internet]. 2014 [cited 2016 Jan 5]. Available from: http://www.nanbyou.or.jp/entry/3627.
19. P.Song, Y.Inagaki, Y.Sugawara, et al. Perspectives on human clinical trials of therapies using iPS cells in Japan: reaching the forefront of stem-cell therapies. Biosci Trends. 2013 Jun;7(3):157–158.
20. The MHLW Grants System. The research against intractable liver diseases [Internet]. 2013 [cited 2016 Jan 5]. Available from: http://mhlw-grants.niph.go.jp/niph/search/NIDD00do?resrchNum=201231041A
21. Japan Intractable Diseases Information Center. The guideline for diagnosis and treatment [Internet]. 2015 [cited 2016 Jan 6]. Available from: http://www.nanbyou.or.jp/entry/504#01.
22. Japan Intractable Diseases Information Center. The center hospital for treatment of rare diseases [Internet]. 2014 [cited 2016 Jan 7]. Available from: http://www.nanbyou.or.jp/entry/1439.
23. Japan Intractable Diseases Information Center. The cooperative hospital for treatment of rare diseases [Internet]. 2014 [cited 2016 Jan 7]. Available from: http://www.nanbyou.or.jp/entry/1611.
24. Japan Intractable Diseases Information Center. Specified disease treatment research program on 130 diseases [Internet]. 2014 [cited 2015 Dec 28]. Available from: http://www.nanbyou.or.jp/entry/511
25. T.Kodama, N.Tomita. Global movement for diagnosis and treatment of rare/intractable diseases. J Natl Inst Public Health. 2011;60:105–111. (in Japanese).
26. H.Nakatani, T.Kondo. Characteristics of a medical care program for specific diseases in Japan in an era of changing cost-sharing. Health Policy. 2003 Jun;64(3):377–389.
27. S.Hayashi, T.Umeda. 35 years of Japanese policy on rare diseases. Lancet. 2008 Sep 13;372(9642):889–890.
28. P.Franco. Orphan drugs: the regulatory environment. Drug Discov Today. 2013 Feb;18(3–4):163–172.• Article describing the orphan drugs designation in Japan, the USA, and the EU.
29. E.Tambuyzer. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010 Dec;9(12):921–929.
30. C.Schey, T.Milanova, A.Hutchings. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
31. Pharmaceuticals and Medical Devices Agency. The business report in 2010 [Internet]. 2010 [cited 2015 Dec 15]. Available from: https://www.pmda.go.jp/english/about-pmda/annual-reports/0001.html
32. K.Tsuji, K.Tsutani. Personal imports of drugs to Japan in 2005 – an analysis of import certificates. J Clin Pharm Ther. 2008 Oct;33(5):545–552.
33. Keio University Hospital Clinical and translation Research Center [Internet]. 2014 [cited 2015 Dec 27]. Available from: http://www.hosp.keio.ac.jp/ctr/about/outline.html
34. T.Moritoyo. Accelerating regulatory science initiatives for the development of drugs for Alzheimer’s disease in Japan. Clin Ther. 2015 Aug;37(8):1622–1626.